Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 2/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29750488 | 1.00 | ALDH1A1 (0.63) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL7358514 | 0.92 | ALDH1A1 (0.54) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL7358507 | 0.92 | ALDH1A1 (0.54) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| Pyrrole SCHEMBL11894210 | 0.92 | ALDH1A1 (0.54) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL3851835 | 0.92 | SRC (0.63) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL7361573 | 0.87 | ALDH1A1 (0.49) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL9013565 | 0.87 | ALDH1A1 (0.49) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL17585067 | 0.85 | HPGD (0.44) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL8470135 | 0.84 | PTGDR2 (0.46) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL635622 | 0.82 | ALDH1A1 (0.54) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110431144-B | Cyano-substituted heteroaryl pyrimidone derivatives, and preparation method and application thereof | 浙江海正药业股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| US-11142531-B2 | Cyano substituted heteroarylpyrimidinone derivative, preparation method and use thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2021-10-12 | — | — | US | disclosed |
| US-11142531-B2 | Cyano substituted heteroarylpyrimidinone derivative, preparation method and use thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2021-10-12 | — | — | US | disclosed |
| EP-3814348-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200102322-A1 | CYANO SUBSTITUTED HETEROARYLPYRIMIDINONE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2020-04-02 | — | — | US | disclosed |
| US-20200102322-A1 | CYANO SUBSTITUTED HETEROARYLPYRIMIDINONE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2020-04-02 | — | — | US | disclosed |
| CN-110431144-A | The heteroaryl hepyramine analog derivative and its preparation method and application that cyano replaces | ZHEJIANG HISUN PHARM CO LTD | 2019-11-08 | — | — | CN | disclosed |
| US-9518015-B2 | EP1 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-12-13 | — | — | US | disclosed |
| CN-102666545-B | As the heterocycle Pyrazolopyrimidine analogs of JAK inhibitor | CELLZOME LTD. (GB) | 2016-04-06 | — | — | CN | disclosed |
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| EP-0088276-B1 | COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL PREPARATIONS | BAYER AG (DE) | 1986-04-30 | — | — | EP | disclosed |
| US-4565824-A | Certain nitratoalkyl ester dihydropyridines having antihypertensive properties | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-21 | — | — | US | disclosed |
| US-4551467-A | Vasodilating cyanoalkyl esters of 1,4-dihydropyridines | BAYER AKTIENGESELLSCHAFT (DE) | 1985-11-05 | — | — | US | disclosed |
| EP-0110259-A1 | 1,4-Dihydropyridines, processes for their preparation and their use in medicines | BAYER AG (DE) | 1984-06-13 | — | — | EP | disclosed |
| EP-0088276-A1 | Compounds, process for their preparation and their use as pharmaceutical preparations | BAYER AG (DE) | 1983-09-14 | — | — | EP | disclosed |
| EP-0039863-A1 | 1,4-Dihydropyridines with different substituents in positions 2 and 6, processes for their preparation and their use in medicines | BAYER AG (DE) | 1981-11-18 | — | — | EP | disclosed |
| US-4248873-A | Nitro-substituted 1,4-dihydropyridines, processes for _their production and their medicinal use | BAYER AKTIENGESELLSCHAFT (DE) | 1981-02-03 | — | — | US | disclosed |
| EP-0012180-A1 | 1,4-Dihydropyridine compounds, their preparation, pharmaceutical compositions containing said compounds and preparation of these compositions | BAYER AG (DE) | 1980-06-25 | — | — | EP | disclosed |
| US-4179500-A | 1,4-Dihydropyridine-sugar derivatives, and their use as medicaments | BAYER AKTIENGESELLSCHAFT (DE) | 1979-12-18 | — | — | US | disclosed |
| EP-0002208-A1 | Nitro 1,4-dihydropyridines, medicaments containing them and their manufacture | BAYER AG (DE) | 1979-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102322-A1 | CYANO SUBSTITUTED HETEROARYLPYRIMIDINONE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | ACACA, COASY, ACACB | ALDH1A1 161/4885HPGD 307/4885HTT 3491/4885 |
| US-11142531-B2 | Cyano substituted heteroarylpyrimidinone derivative, preparation method and use thereof | ACACA, COASY, ACACB | ALDH1A1 161/4885HPGD 307/4885HTT 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.